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Background: Consumption of marine-based oils high in omega-3 polyunsaturated fatty acids (n3PUFAs),
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is known to protect against obesity-related
pathologies. It is less clear whether traditional vegetable oils with high omega-6 polyunsaturated fatty acid
(n6PUFA) content exhibit similar therapeutic benefits. As such, this study examined the metabolic effects of a
plant-based n3PUFA, stearidonic acid (SDA), in polygenic obese rodents.
Methods: Lean (LZR) and obese Zucker (OZR) rats were provided either a standard westernized control diet (CON)
with a high n6PUFA to n3PUFA ratio (i.e., 16.2/1.0) or experimental diet modified with flaxseed (FLAX), menhaden
(FISH), or SDA oil that resulted in n6PUFA to n3PUFA ratios of 1.7/1.0, 1.3/1.0, and 1.0/0.8, respectively.
Results: After 12 weeks, total adiposity, dyslipidemia, glucose intolerance, and hepatic steatosis were all greater,
whereas n3PUFA content in liver, adipose, and muscle was lower in OZR vs. LZR rats. Obese rodents fed modified
FISH or SDA diets had lower serum lipids and hepatic fat content vs. CON. The omega-3 index (i.e., ΣEPA + DHA in
erythrocyte membrane) was 4.0, 2.4, and 2.0-fold greater in rodents provided FISH, SDA, and FLAX vs. CON diet,
irrespective of genotype. Total hepatic n3PUFA and DHA was highest in rats fed FISH, whereas both hepatic and
extra-hepatic EPA was higher with FISH and SDA groups.
Conclusions: These data indicate that SDA oil represents a viable plant-derived source of n3PUFA, which has
therapeutic implications for several obesity-related pathologies.
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Epidemiological and interventional studies [1-3] have
shown that dietary intake of omega-3 polyunsaturated
fatty acids (n3PUFAs) such as eicosapentaenoic acid (EPA;
20:5 n3) and docosahexaenoic acid (DHA; 22:6 n3) are
associated with a reduced risk of metabolic disease. Add-
itional evidence has demonstrated a therapeutic role of
n3PUFAs on obesity-related pathologies including inflam-
mation, dyslipidemia, and insulin resistance [4-6]. EPA
and DHA consumption is associated with a reduced risk
of sudden death and death from coronary artery disease,
which forms the basis of the American Heart Association’s* Correspondence: jedavis@siu.edu
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reproduction in any medium, provided the orrecommendation that individuals with documented coron-
ary disease consume about 1.0 g/d of EPA/DHA [7]. It re-
mains to be determined whether the cardioprotective
effect of the long chain n3PUFA are due to effects on me-
tabolism in general or due to cardiac specific effects.
Nonalcoholic fatty liver disease (NAFLD), character-
ized by excessive hepatic fat accumulation, is associated
with increased risk of cardiovascular disease [8]. Current
treatment modalities for NAFLD are primarily based on
weight loss and lifestyle modification [9]. However, sci-
entific evidence in the form of clinical studies is lacking
in this area; thus, the relative efficacy of various ap-
proaches remains unknown for the majority of the popu-
lation. On the other hand, EPA and DHA intake is
reported to consistently protect against hepatic steatosis
[10-12]. In support of this, a recent meta-analysis [13]td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Composition of experimental diets†
Ingredients‡ (g/kg) CON FLAX FISH SDA
Casein, Sodium 200 200 200 200
L-Cystine 3 3 3 3
Corn Starch 240 240 240 240
Maltodextrin 75 75 75 75
Sucrose 100 100 100 100
Cellulose 50 50 50 50
Cocoa Butter, Deodorized 37.5 37.5 37.5 37.5
Coconut Oil 2.5 2.5 2.5 10.6
Flaxseed Oil 4.5 31.5 4.5 4.5
Menhaden Oil – – 53 –
Palm Oil, Deodorized 50 50 24 8.8
Safflower Oil 55.5 28.5 28.5 –
SDA Soybean Oil – – – 88.6
Fatty acids composition* (% of total fat)
ΣSFA 38.82 38.77 38.77 35.39
ΣMUFA 28.01 28.29 26.71 22.26
Σn3PUFA 1.83 11.93 13.65 23.11
ALA[18:3] 1.83 11.93 2.32 9.24
SDA[18:4] – – 1.01 13.87
EPA[20:5] – – 4.78 –
DHA[22:6] – – 4.18 –
Σn6PUFA 29.8 20.4 17.78 18.78
LA[18:2] 29.8 20.4 17.1 15.1
GLA[18:3] – – – 3.68
AA[20:4] – – 0.32 –
†Adapted from US17 Monsanto Diet (21% kcal protein, 44% kcal carbohydrate,
35% kcal fat) [28].
‡Additional ingredients: t-BHQ, 0.03 g; mineral mix, 10 g; dicalcium phosphate,
13 g; calcium carbonate, 5.5 g; potassium citrate, 16.5 g; vitamin mix, 10 g;
choline bitartrate, 2 g; alpha vitamin E acetate (500 IU/g), 0.13 g.
*Fatty Acid Analysis provided by NP Analytical Labs (St. Louis, MO).
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duced liver fat in patients diagnosed with NAFLD.
In Europe as well as the United States, dietary intake of
EPA and DHA is well below recommended levels [14,15].
Potential reasons for this disparity include food prefer-
ences, economic limitations, and concerns regarding envir-
onmental contaminants [16,17]. Additional dietary sources
of n3PUFAs—such as flaxseed, canola, and soybean—
represent an alternative to fish and fish oils. However,
plant-based n3PUFAs are typically higher in α-linolenic
acid (ALA; 18:3 n3) compared to EPA and DHA [18].
Although ALA can be converted to EPA and DHA, the
overall efficiency is low with conversion ranging from
0.01% to 8% in males or up to 21% in females [19,20].
The rate limiting step for biosynthesis of EPA from ALA
is catalyzed by delta-6 desaturase (Fads2). The product of
this specific reaction is stearidonic acid (SDA; 18:4 n3),
which is readily catalyzed to EPA by the enzymes elongase
(Elovl2/5) and delta-5 desaturase (Fads1) [21]. SDA con-
centrations in marine and plant based oils are typically
low; however, it can be intentionally increased in legumes,
such as soybean through biotechnology [15]. The con-
sumption of SDA-ethyl esters or SDA-enriched soybean
oil is shown to enhance EPA enrichment in humans
[22-25]. James et al. [23] specifically demonstrated that the
relative efficiency of SDA to enhance EPA concentration
in erythrocytes was about 16%, whereas ALA was ~7%.
Such observations underlie the potential benefit of SDA-
enriched soybean oil to increase in vivo concentration of
long chain n3PUFA.
Currently, there is only a limited amount of data on the
relationship between dietary intake of high SDA oils and
obesity-associated pathologies. Two studies with echium
oil (~12% SDA) have reported anti-hyperlipidemic and
hepatoprotective effects in obesity [26,27]. As such, there
is a strong likelihood that SDA-enriched soybean oil may
have similar impact on the progression of obesity-related
comorbidities. The objectives of the present study were to
(i) characterize the effect of SDA-enriched soybean oil on
n3PUFA enrichment and metabolic dysfunction in obese
rodents, and (ii) compare and contrast these effects with
traditional marine (i.e. menhaden oil) and plant-based
(i.e., flaxseed oil) sources of n3PUFAs.
Methods
Animals and diets
Twenty-four male homozygous OZR (fa/fa), and age-
matched LZR (+/fa) rats (Harlan Laboratory, Indianapolis,
IN) were randomly assigned to four diet groups (n = 6) at
six weeks of age. Animals were fed ad libitum while
housed in individual hanging wire cages in a temperature
controlled room with a 12 hour light–dark cycle. Prior to
termination, animals were fasted overnight. All exp-
erimental protocols applied for animal care and use wereapproved by the Animal Care and Use Committee of
Southern Illinois University, Carbondale, IL.
All animals were acclimated on a standard rodent
chow for one week prior to study initiation. Control
(CON) and experimental diets (Research Diets, Inc.,
New Brunswick, NJ) were modified from the previously
used US17 Monsanto diet [28]. All diets were formu-
lated to be isocaloric and isonitrogenous (Table 1). The
CON diet was designed to reflect a typical Western diet
with a high n6PUFA to n3PUFA ratio (i.e., 16.2 to 1).
The n6PUFA and n3PUFA content of experimental diets
was modified by incorporation of flaxseed (FLAX), men-
haden (FISH), or SDA oil. To ensure that saturated and
monounsaturated fat content was consistent in the ex-
perimental diets, the percentage of FLAX, FISH, or SDA
oil used was varied (i.e., 7.4%, 12.6%, and 20.6% of total
kcal, respectively). As such, the PUFA to saturated fat
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oxidation of oils, all diets were stored at −20°C and pro-
vided daily. The fatty acid analysis for each diet is
presented in Table 1.Anthropometric and serum measurements
Body weight and food intake were collected daily. Whole
body and liver compositions (i.e., lean, fat, and water) were
determined using an EchoMRI-900™ Bioanalyzer (Echo
Medical Systems, LLC). At 12 weeks, rodents were fasted
overnight and euthanized by CO2 asphyxiation and decapi-
tation. Trunk blood was collected and used for subsequent
analysis. All tissues were snapped frozen in liquid nitrogen
prior to storage at −80°C. Extracted serum was analyzed
for cholesterol and triacylglycerol (TAG) (Beckman CX4
Chemistry Analyzer, Brea, CA). Additionally, serum insulin
(Millipore, Billerica, MA) and glucose (BioVision, Milpitas,
CA) were determined using appropriate assays. The fatty
acid profile of erythrocyte membranes was also measured
using capillary gas chromatography by OmegaQuant, LLC
(Sioux Falls, SD) as previously described [22].Oral glucose tolerance test (OGTT)
Prior to termination, OGTTs were performed as de-
scribed [29]. Briefly, a glucose solution (2 g/kg) was ad-
ministered by oral gavage and blood samples were
collected at 0, 15, 30, 60, and 120 min.Tissue fatty acid analysis
Liver, brain, adipose tissue (AT), and soleus tissue sam-
ples were measured to 500 mg and put into glass test
tubes (16×200 mm) with Teflon-lined screw caps, stored
at −80°C for 6h, freeze-dried, and then methylated using
the NaOCH3 and HCl two-step procedure [30]. Methylated
fatty acids were then analyzed for fatty acids using a
Shimadzu GC-2010 gas chromatograph (Shimadzu
Scientific Instruments Inc., Columbia, MD) equipped
with a flame ionization detector and a Supelco 100-m
SP-2560 fused silica capillary column (0.25 mm i.d. ×
0.2 μm film thickness). The helium carrier gas was
maintained at a linear velocity of 23 cm/s. The oven
temperature was programmed for 135°C for 5 min, then
increased at 5°C/min to 165°C, held there for 80 min, then
increased at 3°C/min to 180°C, then increased at 5°C/min
to 245°C and held there for 9 min. The injector and de-
tector temperatures were set at 255°C. Peaks were iden-
tified by comparing the retention times with those of
corresponding standards (Nu-Chek Prep, Elysian, MN;
Supelco, Bellefonte, PA; and Larodan Fine Chemicals,
Malmo, Sweden). Heptadecanoic acid (C17:0) was added
to all samples as an internal standard.Hepatic transcript abundance
Total RNA was extracted from liver using Tri Reagent
(Molecular Research Center, Inc., Cincinnati, OH) and
RNeasy mini columns (QIAGEN Inc., Valencia, CA) as
previously described [29]. Purified mRNA was reverse
transcribed to cDNA with RT2 PCR Array First Strand Kit
and assayed with customized RT2 Profiler PCR Arrays
(SABiosciences, Frederick, MD) using gene-specific pri-
mers (manufacturer’s proprietary primers, sequences not
disclosed). cDNA was diluted into RT2 SYBR Green Mas-
ter Mix (SABiosciences) and quantitative real time PCR
was performed using a MyiQ Real-Time PCR Detection
System (Bio-Rad, Hercules, CA). Real time PCRs were
performed as follows: melting for 10min at 95°C, 40 cy-
cles of two-step PCR including melting for 15sec at 95 °C,
annealing for 1min at 60°C. All cycle threshold (Ct) values
of > 35.0 were considered non-cycling and removed from
analysis. The raw data were analyzed with the ΔΔCt
method [31] using a web-based software program pro-
vided by the manufacturer. Data were presented as fold
change relative to LZR fed control diet.Statistical analysis
Data were tested for normality and analyzed using the
mixed-model analysis with Bonferroni adjustment (SAS
Institute, Inc., Cary, NC). Diet and genotype were con-
sidered fixed effects. The least significant means
(LSMEANS) ± standard error of mean (SEM) are pres-
ented in tables and figures. When the interaction of main
effects was protected by a significant F-value, post hoc
comparisons were made using the LSMEANS separation
(pdiff) procedure. Differences among LSMEANS were
considered significant at P < 0.05. Significant main effects
(diet and genotype) are also presented in tables and figure
legends. This standard analysis was performed for all mea-
sures unless otherwise specified.Results
Body composition and plasma markers
Energy intake, body weight, and body fat were greater
(Table 2; Genotype, P < 0.0001), whereas lean body mass
was lower in obese vs. lean rodents (Genotype, P <
0.0001). There was no significant effect of diet on en-
ergy intake (Diet, P = 0.10), body weight (Diet, P = 0.47),
body fat mass (Diet, P = 0.07), or lean body mass (Diet,
P = 0.61). As expected, dyslipidemia was greater in
obese vs. lean rodents (Figure 1; Genotype, P < 0.0001).
Serum cholesterol and TAG concentration were lower
with SDA or FISH vs. CON and FLAX (Diet, P <
0.0001). Although glucose intolerance, glucose to insu-
lin ratio, and plasma insulin were greater in obese vs.
lean rodents (Table 2; Genotype, P = 0.017, P = 0.0003,
and P = 0.0057, respectively), there was no significant
Table 2 Morphometric and metabolic parameters in LZR and OZR rats fed CON, FLAX, FISH, or SDA diets for 12 weeks
Lean Obese Main effects
CON FLAX FISH SDA CON FLAX FISH SDA Genotype Diet Interaction
Total EI (kcal) 7588 ± 231 7381 ± 230 7296 ± 228 7276 ± 235 9208 ± 249 9595 ± 219 9069 ± 238 8824 ± 264 P < 0.0001‡ P = 0.09 P = 0.30
Body weight (g) 497.9 ± 15.7 481.3 ± 15.6 487.8 ± 15.4 485.7 ± 15.9 635.6 ± 16.8 647.7 ± 14.9 626.7 ± 16.1 611.0 ± 17.9 P < 0.0001‡ P = 0.47 P = 0.43
Body fat mass (%) 15.35 ± 0.98 15.24 ± 0.97 15.53 ± 0.96 13.53 ± 0.99 47.79 ± 1.05 49.86 ± 0.93 48.23 ± 1.01 45.84 ± 1.12 P < 0.0001‡ P = 0.0038i P = 0.22
Body lean mass (%) 68.27 ± 0.85 68.58 ± 0.84 68.09 ± 0.84 69.68 ± 0.86 40.31 ± 0.91 38.87 ± 0.81 39.75 ± 0.87 41.31 ± 0.97 P < 0.0001† P = 0.050ii P = 0.61
Adj. liver weight (%) 2.60 ± 0.16 2.67 ± 0.16 2.88 ± 0.16 2.79 ± 0.16 3.67 ± 0.17 3.75 ± 0.15 3.49 ± 0.16 3.41 ± 0.18 P < 0.0001‡ P = 0.81 P = 0.17
Liver fat mass (%) 9.15 ± 1.36a 8.01 ± 1.35a 10.30 ± 1.34a 9.22 ± 1.39a 20.52 ± 1.45cd 21.72 ± 1.28d 15.97 ± 1.38b 18.60 ± 1.48bc P < 0.0001‡ P = 0.37 ΔP = 0.0053
Liver lean mass (%) 87.47 ± 1.73c 85.41 ± 1.72c 86.10 ± 1.70c 84.04 ± 1.76c 73.05 ± 1.44a 72.94 ± 1.62a 78.46 ± 1.35b 76.56 ± 1.48b P < 0.0001† P = 0.19 ΔP = 0.039
Glucose (AUC) 2580 ± 173 2364 ± 171 2618 ± 170 2540 ± 176 2740 ± 184 2544 ± 174 3055 ± 176 3074 ± 189 P = 0.017 P = 0.35 P = 0.46
Glucose to insulin ratio 17.69 ± 3.40 23.54 ± 3.32 17.37 ± 3.28 18.46 ± 3.42 1.15 ± 3.50 4.32 ± 3.31 1.21 ± 3.34 1.45 ± 3.59 P = 0.0003‡ P = 0.28 P = 0.77
Insulin (pmol/L) 0.90 ± 1.10 0.83 ± 1.07 2.32 ± 1.06 1.00 ± 1.10 5.92 ± 1.16 4.09 ± 1.07 6.19 ± 1.08 5.57 ± 1.16 P = 0.0057‡ P = 0.25 P = 0.94
ΔDifferent letters represent significance among means as determined by Bonferroni correction (P < 0.05).
Genotype Effect: †Lean > Obese; ‡Obese > Lean.






















Figure 1 Serum cholesterol and triacylglyceride concentrations in LZR and OZR rats provided CON, FLAX, FISH, or SDA diets for 12
weeks. All graphed values represent LS interaction means ± SE. Letters represent significant differences among means as determined by the
Bonferroni correction. A) Serum cholesterol expressed as mmol/L (n = 6, Genotype effect, P < 0.0001 (Obese > Lean); Diet effect, P < 0.0001
(CON, FLAX > FISH, SDA); Diet*Genotype interaction, P = 0.094). B) Serum triacylglyceride expressed as mmol/L (n = 6, Genotype effect, P = 0.0002
(Obese > Lean); Diet effect, P = 0.0065 (CON, FLAX > FISH, SDA); Diet*Genotype interaction, P = 0.93).
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and P = 0.25, respectively).Erythrocyte membrane fatty acid composition
In erythrocytes, the percentage of EPA, DHA, MUFA, and
n3PUFA were greater; whereas, LA and n6PUFA were
lower in obese vs. lean rodents (Table 3; Genotype, P <
0.001). All n3PUFA-enriched diets (FLAX, FISH, and
SDA) increased omega-3 index in OZR rats (Figure 2;
Genotype*Diet, P < 0.0001). Moreover, the percentage of
EPA, DPA, and n3PUFA were greater; whereas, AA and
n6PUFA were lower with FLAX, FISH, or SDA vs. CON
(Diet, P < 0.0001). Omega-3 index, as well as the percent-
age of EPA, DHA, and n3PUFA, was greatest with FISH
compared to remaining n3PUFA-enriched diets (Diet, P <
0.0001). In contrast, the percentage of GLA, SDA, and
DPA were greatest with SDA (Diet, P < 0.0001). The SDA
diet also resulted in a greater percentage of EPA and
n3PUFA, as well as a lower percentage of LA, AA, and
n6PUFA compared to FLAX (Diet, P < 0.0001).Hepatic metabolic profile
Liver weight and fat content were greater; while, lean
mass was lower in obese vs. lean rodents (Table 2; Geno-
type, P < 0.0001). Independently of genotype, there was
no significant difference in liver weight (Diet, P = 0.81),
fat content (Diet, P = 0.37) or lean mass (Diet, P = 0.19).
However, hepatic fat content in obese rodents was unex-
pectedly greater with FLAX vs. FISH or SDA (Gen*Diet,
P < 0.0001). In contrast, the hepatic lean mass in OZR
rats was lower with CON and FLAX compared to SDA
or FISH (Gen*Diet, P < 0.05).
Hepatic fatty acid composition
The percentage of ALA, AA, DPA, DHA, MUFA,
n3PUFA, and n6PUFA were lower, whereas SFA was
greater in liver of obese vs. lean rodents (Table 4; Geno-
type, P < 0.05). All n3PUFA-enriched diets had a greater
percentage of DPA, DHA, and n3PUFA, as well as lower
percentage of AA and n6PUFA in liver (Diet, P < 0.0001).
The percentage of DPA, DHA and n3PUFA were greater;
while the percentage of AA and n6PUFA were lower with
Table 3 Erythrocyte membrane fatty acid composition in LZR and OZR rats fed CON, FLAX, FISH, or SDA diets for 12 weeks
Fatty acid
(% of total)
Lean Obese Main effects
CON FLAX FISH SDA CON FLAX FISH SDA Genotype Diet Interaction
LA[18:2(n-6)] 9.50 ± 0.28 9.61 ± 0.28 9.72 ± 0.28 8.26 ± 0.29 7.76 ± 0.30 7.97 ± 0.29 8.21 ± 0.29 6.73 ± 0.31 P < 0.0001† P < 0.0001i P = 0.96
ALA[18:3(n-3)] 0.04 ± 0.07a 0.43 ± 0.07b 0.10 ± 0.07a 0.64 ± 0.07c 0.14 ± 0.07a 0.70 ± 0.07c 0.21 ± 0.07a 0.61 ± 0.08bc P = 0.24 P < 0.0001ii ΔP = 0.079
GLA[18:3(n-3)] 0.04 ± 0.02 0.04 ± 0.02 0.04 ± 0.02 0.30 ± 0.02 0.05 ± 0.02 0.04 ± 0.02 0.04 ± 0.02 0.20 ± 0.02 P = 0.78 P < 0.0001iii P = 0.52
SDA[18:4(n-3)] 0.03 ± 0.05 0.03 ± 0.05 0.03 ± 0.05 0.40 ± 0.05 0.03 ± 0.03 0.02 ± 0.05 0.03 ± 0.05 0.40 ± 0.05 P = 0.74 P < 0.0001iii P = 0.76
AA[20:4(n-6)] 25.63 ± 0.51 22.21 ± 0.51 15.90 ± 0.50 20.67 ± 0.52 24.91 ± 0.54 21.1 ± 0.51 14.80 ± 0.52 18.13 ± 0.56 P = 0.056 P < 0.0001iv P = 0.13
EPA[20:5(n-3)] 0.05 ± 0.11a 1.06 ± 0.11b 5.14 ± 0.11f 2.80 ± 0.11d 0.23 ± 0.12a 1.45 ± 0.11c 5.41 ± 0.12f 3.98 ± 0.12e P = 0.0017‡ P < 0.0001v ΔP < 0.0001
DPA[22:5(n-3)] 1.02 ± 0.16a 3.67 ± 0.16cd 3.74 ± 0.16d 5.44 ± 0.17e 1.19 ± 0.17a 3.08 ± 0.17b 3.17 ± 0.18bc 4.64 ± 0.18e P = 0.052 P < 0.0001vi ΔP = 0.0050
DHA[22:6(n-3)] 2.51 ± 0.14 3.74 ± 0.14 5.80 ± 0.14 2.31 ± 0.14 2.91 ± 0.15 4.33 ± 0.14 6.50 ± 0.14 3.28 ± 0.15 P = 0.0010‡ P < 0.0001vii P = 0.10
∑SFA 47.53 ± 0.39 47.58 ± 0.39 47.17 ± 0.38 47.49 ± 0.40 47.35 ± 0.41 47.23 ± 0.39 47.67 ± 0.40 47.31 ± 0.43 P = 0.93 P = 0.99 P = 0.56
∑MUFA 9.62 ± 0.39 9.94 ± 0.39 11.00 ± 0.39 10.14 ± 0.40 11.91 ± 0.42 12.12 ± 0.40 12.12 ± 0.40 12.36 ± 0.43 P = 0.0006‡ P = 0.11 P = 0.23
∑n3PUFA 3.63 ± 0.19 8.92 ± 0.19 14.81 ± 0.19 11.63 ± 0.20 4.48 ± 0.20 9.59 ± 0.19 15.31 ± 0.20 12.88 ± 0.21 P = 0.0029‡ P < 0.0001v P = 0.10
∑n6PUFA 41.23 ± 0.45 37.23 ± 0.45 32.76 ± 0.44 33.01 ± 0.46 38.61 ± 0.48 35.33 ± 0.45 31.33 ± 0.46 30.67 ± 0.49 P = 0.0013† P < 0.0001iv P = 0.41
ΔDifferent letters represent significance among means as determined by Bonferroni correction (P < 0.05).
Genotype Effect: †Lean > Obese; ‡Obese > Lean.






















Figure 2 Erythrocyte membrane Omega-3 Index in LZR and OZR
rats fed CON, FLAX, FISH, or SDA diets for 12 weeks. Omega-3
Index (%EPA +%DHA) was calculated from RBC membranes as
described [22]. All graphed values represent LS interaction means ±
SE. Letters represent significant differences among means as
determined by the Bonferroni correction (n = 6, Genotype effect, P <
0.0001 (Obese > Lean); Diet effect, P < 0.0001 (FISH > SDA > FLAX >
CON); Diet*Genotype interaction, P < 0.0001).
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percentage of SDA, EPA, DPA, and n3PUFA were greater;
whereas, the percentage SFA and MUFA were lower with
SDA vs. FLAX (Diet, P < 0.05).
Corresponding with these changes in fatty acid profile,
there were distinct modification to genes involved in fatty
acid elongation and desaturation (Table 5). In particular,
hepatic transcript abundance of Scd1, Fads1, Fads2, Elov5,
Elov6, and PPARα was greater in obese rodents (P < 0.05).
Additionally, transcript abundance of Fads1, Fads2, Elvol5,
and Elvol6 in LZR rats was greater with FLAX vs. SDA or
FISH (P < 0.05). Similarly, hepatic transcript abundance of
Fads2, Elvol5, and Elvol6 in obese rodents was greater
with FLAX vs. SDA or FISH (P < 0.05).
Extrahepatic fatty acid composition
Epidydimal AT
The percentage of ALA, SDA, n3PUFA, and MUFA were
lower, whereas the percentage of SFA was greater in
epidydimal AT of obese vs. lean rodents (Table 6; Geno-
type, P < 0.0001). There was also a greater percentage of
ALA, DPA, and n3PUFA, as well as lower percentage of
AA, MUFA, and n6PUFA with all n3PUFA-enriched di-
ets compared to CON (Diet, P < 0.0001). The percent-
age of EPA, DPA, DHA, and SFA were greater with
FISH vs. FLAX or SDA (Diet, P < 0.0001). In contrast,
the percentage of SDA was greater; while, the percent-
age of LA, MUFA, and SFA was lower with SDA vs.
FISH and FLAX (Diet, P < 0.0001). The percentage of
ALA was greater with FLAX vs. FISH or SDA (Diet, P <
0.0001). Additionally, the percentage of EPA, DPA,DHA, and AA content was lower with FLAX compared
to SDA (P < 0.0001).Subcutaneous AT
The percentage of ALA, SDA, MUFA, n3PUFA were
lower; whereas, the percentage of DPA, DHA, and SFA
were greater in subcutaneous AT of obese vs. lean rodents
(Table 7; Genotype, P < 0.0001). The percentage of DPA
and MUFA was greater; while the percentage of ALA and
n3PUFA were lower in subcutaneous AT with all
n3PUFA-enriched diets (Diet, P < 0.0001). Similar to
epidydimal AT, the percentage of EPA, DPA, DHA, and
SFA were greater with FISH vs. FLAX or SDA (Diet, P <
0.0001). However, the percentage of SDA, AA, and
n3PUFA were greater with SDA vs. FISH or FLAX (Diet,
P < 0.0001). Compared to FLAX, the percentage of EPA,
DPA, and DHA were lower with SDA (Diet, P < 0.0001).Soleus muscle
The percentage of SDA and n3PUFA were lower in so-
leus muscle of obese vs. lean rodents (Table 8; Genotype,
P < 0.0001). The percentage of n3PUFA was greater;
while, the percentage of AA and n6PUFA were lower
with all n3PUFA-enriched diets (Diet, P < 0.0001). Unlike
AT depots, there was no difference in EPA or DHA con-
tent between FISH and SDA (Diet, P = 0.94 and P = 0.34,
respectively). Moreover, the percentage of EPA and
DHA was greater with FISH or SDA vs. CON and FLAX
(Diet, P < 0.05). The percentage of LA (Diet, P < 0.05),
SDA (Diet, P < 0.0001), DPA (Diet, P < 0.0001) and
n3PUFA (Diet, P < 0.05) were also greater with SDA vs.
FISH or FLAX. Additionally, the percentage of EPA and
DPA were greater; whereas, the percentage of MUFA
was lower in SDA vs. FLAX (Diet, P < 0.0001).Brain
The percentage of EPA, DPA, and DHA were greater,
whereas, the percentage of ALA and MUFA were lower
in brain tissue of obese vs. lean rodents (Table 9; Geno-
type, P < 0.0001). Overall, there was a greater percentage
of EPA, DHA, and n3PUFA (Diet, P < 0.0001); whereas,
the percentage of AA and n6PUFA was lower with all
n3PUFA-enriched diets (Diet, P < 0.05). The percentage
of EPA and DHA were greater; while, the percentage of
AA and n6PUFA was lower with FISH vs. FLAX or SDA
(Diet, P < 0.0001). In contrast, the percentage of DPA
was greater; while, the percentage of ALA was lower
with SDA vs. FISH and FLAX (Diet, P < 0.0001). The
percentage of ALA was greater with FLAX vs. FISH or
SDA (Diet, P < 0.05). However, the percentage of EPA
and n3PUFA was lower with FLAX vs. SDA (Diet, P <
0.0001).
Table 4 Hepatic fatty acid composition in LZR and OZR rats fed CON, FLAX, FISH, or SDA diets for 12 weeks
Fatty acid
(% of total)
Lean Obese Main effects
CON FLAX FISH SDA CON FLAX FISH SDA Genotype Diet Interaction
LA[18:2(n-6)] 1.19 ± 1.41 n.d. n.d. 2.07 ± 1.42 0.86 ± 1.51 0.55 ± 1.19 0.99 ± 1.42 2.08 ± 1.49 P = 0.71 P = 0.25 P = 0.84
ALA[18:3(n-3)] 0.21 ± 0.17a 3.08 ± 0.17d 0.93 ± 0.18b 3.26 ± 0.17d 0.43 ± 0.18ab 1.78 ± 0.14c 0.63 ± 0.17ab 1.88 ± 0.18c P = 0.0016† P < 0.0001i ΔP < 0.0001
SDA[18:4(n-3)] n.d. 0.018 ± 0.26 0.81 ± 0.27 1.07 ± 0.25 0.15 ± 0.27 0.14 ± 0.21 0.19 ± 0.25 0.58 ± 0.26 P = 0.51 P = 0.0011ii P = 0.17
AA[20:4(n-6)] 14.09 ± 0.83c 11.41 ± 0.85b 3.58 ± 0.89a 11.03 ± 0.83b 5.53 ± 0.89a 4.86 ± 0.70a 4.24 ± 0.83a 5.97 ± 0.88a P < 0.0001† P < 0.0001iii ΔP < 0.0001
EPA[20:5(n-3)] n.d. 0.50 ± 0.61a 6.20 ± 0.63c 4.94 ± 0.60c 0.63 ± 0.63a 0.79 ± 0.50a 2.37 ± 0.60b 2.67 ± 0.63b P = 0.12 P < 0.0001ii ΔP < 0.0001
DPA[22:5(n-3)] 0.12 ± 0.22a 1.33 ± 0.23bc 3.36 ± 0.24d 3.94 ± 0.22e 0.42 ± 0.24ab 0.77 ± 0.19b 1.70 ± 0.22c 1.88 ± 0.24c P = 0.0006† P < 0.0001iv ΔP < 0.0001
DHA[22:6(n-3)] 2.26 ± 0.39ab 4.49 ± 0.40cd 10.11 ± 0.42e 3.28 ± 0.39bf 1.87 ± 0.42a 2.43 ± 0.33ab 5.63 ± 0.39d 3.36 ± 0.41bc P = 0.0007† P < 0.0001v ΔP < 0.0001
∑SFA 36.48 ± 1.55c 36.12 ± 1.59c 27.83 ± 1.66a 32.41 ± 1.56b 38.85 ± 1.66d 41.14 ± 1.30d 39.88 ± 1.56d 39.43 ± 1.64d P = 0.0010‡ P = 0.0055vi ΔP = 0.0079
∑MUFA 41.99 ± 1.90 38.02 ± 1.85 33.93 ± 1.94 31.47 ± 1.82 46.57 ± 1.92 44.30 ± 1.51 39.91 ± 1.80 38.08 ± 1.90 P = 0.032† P = 0.0084vi P = 0.90
∑n3PUFA 1.92 ± 1.26a 9.38 ± 1.29b 21.82 ± 1.35d 16.88 ± 1.27c 3.65 ± 1.35a 6.02 ± 1.06e 10.76 ± 1.27b 10.94 ± 1.33b P = 0.048† P < 0.0001iv ΔP = 0.0057
∑n6PUFA 15.28 ± 1.70a 10.6 ± 1.74bc 3.04 ± 1.82d 13.1 ± 1.71ab 6.39 ± 1.82de 5.41 ± 1.43de 5.23 ± 1.71de 8.05 ± 1.80ce P = 0.0040† P < 0.0001iii ΔP < 0.0001
ΔDifferent letters represent significance among means as determined by Bonferroni correction (P < 0.05).
Genotype Effect: †Lean > Obese; ‡Obese > Lean.























Table 5 Hepatic transcript abundance in LZR and OZR rats fed CON, FLAX, FISH, or SDA diets for 12 weeks
Gene
symbol
Gene name Ref. Seq. # Lean Obese
FLAX FISH SDA CON FLAX FISH SDA
Scd1 Stearoyl coenzyme A desaturase 1 NM_139192 1.58a 1.25a 0.43a 8.80b 10.10b 1.49a 7.27b
Fads1 Fatty acid desaturase 1 (Δ5 desaturase) NM_053445 4.92b 2.14a 0.95a 3.49b 3.58b 3.03ab 2.43ab
Fads2 Fatty acid desaturase 2 (Δ6 desaturase) NM_031344 3.44b 2.20a 1.01a 3.86b 4.54c 3.57b 3.62b
Elovl5 Elongation of very long chain fatty acids 5 NM_134382 4.41b 1.81a 0.96a 2.81ab 4.23b 2.28a 2.12a
Elovl6 Elongation of very long chain fatty acids 6 NM_134383 1.94b 0.75a 0.45a 17.39c 50.01d 11.17c 22.84c
Acox1 Acyl coenzyme A oxidase 1 NM_017340 1.54a 1.48a 2.23ab 1.64a 2.22ab 2.45b 2.54b
PPARα Peroxisome proliferator activated receptor α NM_013196 2.38a 1.04a 1.00a 4.14b 4.81b 4.56b 3.94b
Data are expressed as fold change relative to LZR rats fed control diet. Letters represent significance difference among treatments groups as determined by comparison of normalized Ct values (target Ct -






















Table 6 Epidydimal adipose tissue fatty acid profile in LZR and OZR rats fed CON, FLAX, FISH, or SDA diets for 12 weeks
Fatty acid
(% of total)
Lean Obese Main effect
CON FLAX FISH SDA CON FLAX FISH SDA Genotype Diet Interaction
LA[18:2(n-6)] 1.12 ± 0.18 0.87 ± 0.18 0.81 ± 0.18 0.67 ± 0.18 1.33 ± 0.19 1.10 ± 0.17 1.32 ± 0.20 0.86 ± 0.20 P = 0.25 P = 0.025i P = 0.69
ALA[18:3(n-3)] 1.14 ± 0.10ab 7.88 ± 0.11c 1.94 ± 0.10e 7.47 ± 0.11d 0.79 ± 0.11b 5.14 ± 0.10f 1.17 ± 0.12a 4.71 ± 0.12g P < 0.0001† P < 0.0001ii ΔP < 0.0001
SDA[18:4(n-3)] 0.05 ± 0.074a 0.04 ± 0.08a 0.28 ± 0.073c 5.06 ± 0.075b 0.004 ± 0.08a 0.005 ± 0.07a 0.14 ± 0.082a 2.51 ± 0.082d P < 0.0001† P < 0.0001iii ΔP < 0.0001
AA[20:4(n-6)] 0.43 ± 0.03 0.27 ± 0.035 0.35 ± 0.034 0.43 ± 0.04 0.56 ± 0.037 0.32 ± 0.032 0.34 ± 0.038 0.45 ± 0.04 P = 0.36 P < 0.0001iv P = 0.15
EPA[20:5(n-3)] 0.14 ± 0.09 0.15 ± 0.087 1.21 ± 0.086 0.59 ± 0.089 n.d. 0.07 ± 0.08 0.88 ± 0.10 0.51 ± 0.10 P = 0.16 P < 0.0001v P = 0.30
DPA[22:5(n-3)] 0.12 ± 0.07ad 0.24 ± 0.076ad 0.89 ± 0.073c 0.61 ± 0.076b 0.04 ± 0.08a 0.28 ± 0.070d 1.05 ± 0.083c 1.00 ± 0.082c P = 0.20 P < 0.0001vi ΔP = 0.0029
DHA[22:6(n-3)] 0.11 ± 0.10 0.18 ± 0.10 1.69 ± 0.10 0.22 ± 0.10 0.11 ± 0.10 0.33 ± 0.088 1.45 ± 0.10 0.53 ± 0.10 P = 0.82 P < 0.0001v P = 0.52
∑SFA 22.68 ± 0.44a 23.06 ± 0.44a 25.66 ± 0.43c 20.59 ± 0.44b 27.91 ± 0.47d 27.84 ± 0.41d 30.43 ± 0.49e 27.66 ± 0.48d P < 0.0001‡ P < 0.0001vii ΔP < 0.0001
∑MUFA 69.12 ± 0.50a 62.27 ± 0.51b 56.64 ± 0.50d 53.59 ± 0.51c 61.64 ± 0.54b 56.39 ± 0.48d 51.00 ± 0.56e 50.55 ± 0.56e P < 0.0001† P < 0.0001viii ΔP = 0.0055
∑n3PUFA 1.65 ± 0.36a 8.61 ± 0.37d 6.08 ± 0.35c 14.65 ± 0.37f 0.83 ± 0.39a 5.78 ± 0.34c 4.76 ± 0.40b 9.92 ± 0.40e P < 0.0001† P < 0.0001ix ΔP < 0.0001
∑n6PUFA 1.55 ± 0.17 1.15 ± 0.17 1.16 ± 0.17 1.12 ± 0.18 1.88 ± 0.18 1.42 ± 0.16 1.66 ± 0.19 1.31 ± 0.19 P = 0.17 P = 0.0046x P = 0.76
ΔDifferent letters represent significance among means as determined by Bonferroni correction (P < 0.05).
Genotype Effect: †Lean > Obese; ‡Obese > Lean.
Diet Effect: iCON, FISH, FLAX > SDA; iiFLAX > SDA > FISH > CON; iiiSDA > FISH > CON, FLAX; ivCON > SDA > FISH, FLAX; vFISH > SDA > FLAX, CON; viFISH > SDA > FLAX > CON; viiFISH > FLAX, CON > SDA; viiiCON > FLAX >























Table 7 Subcutaneous adipose tissue fatty acid profile in LZR and OZR rats fed CON, FLAX, FISH, or SDA diets for 12 weeks
Fatty acid
(% of total)
Lean Obese Main effect
CON FLAX FISH SDA CON FLAX FISH SDA Genotype Diet Interaction
LA[18:2(n-6)] 0.77 ± 0.24 0.45 ± 0.24 0.57 ± 0.24 0.58 ± 0.24 0.76 ± 0.25 1.16 ± 0.20 0.85 ± 0.24 0.66 ± 0.25 P = 0.36 P = 0.81 P = 0.31
ALA[18:3(n-3)] 0.63 ± 0.15ab 4.72 ± 0.16c 1.23 ± 0.14d 5.03 ± 0.15c 0.49 ± 0.16b 3.61 ± 0.12e 0.92 ± 0.14ad 3.74 ± 0.15e P = 0.0002† P < 0.0001i ΔP < 0.0001
SDA[18:4(n-3)] 0.12 ± 0.10a 0.12 ± 0.11a 0.26 ± 0.10a 2.66 ± 0.11b n.d. n.d. 0.02 ± 0.11a 1.50 ± 0.11c P = 0.0011† P < 0.0001ii ΔP < 0.0001
AA[20:4(n-6)] 0.28 ± 0.020 0.21 ± 0.021 0.29 ± 0.020 0.36 ± 0.020 0.28 ± 0.021 0.20 ± 0.016 0.25 ± 0.020 0.33 ± 0.021 P = 0.46 P < 0.0001iii P = 0.68
EPA[20:5(n-3)] 0.06 ± 0.03a 0.08 ± 0.04a 0.57 ± 0.03cd 0.28 ± 0.04b 0.04 ± 0.04a 0.08 ± 0.03a 0.62 ± 0.03d 0.52 ± 0.04c P = 0.10 P < 0.0001v ΔP < 0.0001
DPA[22:5(n-3)] 0.04 ± 0.03a 0.01 ± 0.03bc 0.46 ± 0.03e 0.32 ± 0.03d 0.05 ± 0.03ab 0.16 ± 0.02c 0.68 ± 0.029f 0.66 ± 0.031f P < 0.0001‡ P < 0.0001vi ΔP < 0.0001
DHA[22:6(n-3)] n.d. 0.03 ± 0.04ab 0.73 ± 0.04c 0.07 ± 0.04ab 0.06 ± 0.04ab 0.13 ± 0.033b 1.12 ± 0.04e 0.33 ± 0.041d P < 0.0001‡ P < 0.0001v ΔP < 0.0001
∑SFA 26.20 ± 1.06 25.55 ± 1.08 27.46 ± 1.05 24.22 ± 1.09 32.27 ± 1.12 31.20 ± 0.88 34.23 ± 1.05 30.42 ± 1.11 P < 0.0001‡ P = 0.0017vii P = 0.94
∑MUFA 66.50 ± 1.10 63.54 ± 1.12 61.57 ± 1.09 58.74 ± 1.13 62.66 ± 1.16 60.48 ± 0.91 55.97 ± 1.09 56.71 ± 1.15 P = 0.0083† P < 0.0001viii P = 0.27
∑n3PUFA 0.87 ± 0.29a 5.10 ± 0.30c 3.42 ± 0.29b 8.68 ± 0.30e 0.57 ± 0.31a 3.98 ± 0.24b 3.52 ± 0.29b 7.50 ± 0.31d P = 0.084† P < 0.0001ix ΔP = 0.030
∑n6PUFA 1.05 ± 0.24 0.66 ± 0.24 0.86 ± 0.24 0.94 ± 0.25 1.04 ± 0.25 1.35 ± 0.20 1.10 ± 0.24 1.00 ± 0.25 P = 0.40 P = 0.98 P = 0.32
ΔDifferent letters represent significance among means as determined by Bonferroni correction (P < 0.05).
Genotype Effect: †Lean > Obese; ‡Obese > Lean.
Diet Effect: iSDA, FLAX > FISH > CON; iiSDA > FISH, FLAX, CON; iiiSDA > FISH, CON > FLAX; ivSDA > FISH > FLAX, CON; vFISH > SDA > FLAX, CON; viFISH > SDA > FLAX > CON; viiFISH > CON, FLAX, SDA; viiiCON > FLAX > FISH,























Table 8 Soleus muscle fatty acid profile in LZR and OZR rats fed CON, FLAX, FISH, or SDA diets for 12 weeks
Fatty acid
(% of total)
Lean Obese Main effect
CON FLAX FISH SDA CON FLAX FISH SDA Genotype Diet Interaction
LA[18:2(n-6)] 0.06 ± 0.02ac 0.007 ± 0.02b 0.02 ± 0.02abc 0.04 ± 0.02abc 0.03 ± 0.01ab 0.02 ± 0.01ab 0.03 ± 0.02ab 0.07 ± 0.01c P = 0.95 P = 0.0045i P = 0.64
ALA[18:3(n-3)] 1.71 ± 0.64 4.79 ± 0.69 1.88 ± 0.67 4.08 ± 0.65 1.80 ± 0.69 3.51 ± 0.54 1.32 ± 0.66 1.80 ± 0.67 P = 0.23 P < 0.0001ii P = 0.18
SDA[18:4(n-3)] 0.66 ± 0.35 0.39 ± 0.38 0.47 ± 0.38 2.72 ± 0.36 0.044 ± 0.38 0.15 ± 0.30 0.19 ± 0.37 0.41 ± 0.37 P = 0.067† P < 0.0001i ΔP = 0.0020
AA[20:4(n-6)] 5.37 ± 0.64b 3.40 ± 0.70a 1.90 ± 0.68a 3.58 ± 0.65a 3.60 ± 0.70ab 2.90 ± 0.54a 3.74 ± 0.67ab 3.63 ± 0.67ab P = 0.91 P = 0.026iii ΔP = 0.019
EPA[20:5(n-3)] 0.41 ± 0.21 0.48 ± 0.22 1.66 ± 0.22 1.41 ± 0.21 0.32 ± 0.22 0.22 ± 0.17 0.85 ± 0.21 1.11 ± 0.21 P = 0.15 P < 0.0001iv P = 0.18
DPA[22:5(n-3)] 1.19 ± 0.33 1.71 ± 0.36 1.69 ± 0.35 2.87 ± 0.34 0.99 ± 0.36 0.95 ± 0.28 1.51 ± 0.34 2.15 ± 0.35 P = 0.28 P < 0.0001i P = 0.58
DHA[22:6(n-3)] 4.14 ± 1.00ac 4.82 ± 1.08ab 7.09 ± 1.06b 4.06 ± 1.01a 2.27 ± 1.08a 1.87 ± 0.84a 3.57 ± 1.03ac 5.01 ± 1.04c P = 0.16 P = 0.054iv ΔP = 0.043
∑SFA 29.69 ± 0.64 29.50 ± 0.70 31.17 ± 0.68 28.54 ± 0.65 30.12 ± 0.70 30.15 ± 0.54 32.38 ± 0.67 30.24 ± 0.68 P = 0.24 P = 0.0004v P = 0.65
∑MUFA 50.76 ± 2.26 51.57 ± 2.45 46.00 ± 2.39 46.86 ± 2.29 56.05 ± 2.45 50.83 ± 1.90 47.21 ± 2.34 42.56 ± 2.36 P = 0.90 P < 0.0001vi P = 0.093
∑n3PUFA 8.32 ± 1.52 12.29 ± 1.65 13.00 ± 1.61 15.63 ± 1.54 5.54 ± 1.65 6.79 ± 1.28 7.67 ± 1.57 10.88 ± 1.59 P = 0.023† P < 0.0001vii P = 0.72
∑n6PUFA 5.41 ± 0.65c 3.41 ± 0.70b 1.92 ± 0.69a 3.62 ± 0.66b 3.62 ± 0.70b 2.91 ± 0.55ab 3.76 ± 0.67b 3.68 ± 0.68b P = 0.91 P = 0.026iii ΔP = 0.020
ΔDifferent letters represent significance among means as determined by Bonferroni correction (P < 0.05).
Genotype Effect: †Lean > Obese; Obese > Lean.






















Table 9 Brain fatty acid profile in LZR and OZR rats fed CON, FLAX, FISH, or SDA diets for 12 week
Fatty acid
(% of total)
Lean Obese Main effect
CON FLAX FISH SDA CON FLAX FISH SDA Genotype Diet Interaction
LA[18:2(n-6)] 0.005 ± 0.002 0.009 ± 0.002 0.005 ± 0.002 0.009 ± 0.002 0.007 ± 0.002 0.007 ± 0.001 0.010 ± 0.002 0.012 ± 0.002 P = 0.13 P = 0.48 P = 0.35
ALA[18:3(n-3)] 1.31 ± 0.030 1.36 ± 0.030 1.28 ± 0.028 1.23 ± 0.030 1.19 ± 0.030 1.20 ± 0.024 1.16 ± 0.030 1.05 ± 0.030 P < 0.0001† P < 0.0001i P = 0.58
SDA[18:4(n-3)] 0.16 ± 0.027 0.14 ± 0.027 0.18 ± 0.026 0.18 ± 0.027 0.08 ± 0.028 0.10 ± 0.022 0.13 ± 0.027 0.12 ± 0.027 P = 0.078 P = 0.30 P = 0.83
AA[20:4(n-6)] 11.02 ± 0.20de 10.69 ± 0.20cd 9.80 ± 0.19b 10.65 ± 0.20cd 11.19 ± 0.21e 10.27 ± 0.16bc 8.87 ± 0.20a 10.48 ± 0.20cd P = 0.16 P < 0.0001ii ΔP = 0.021
EPA[20:5(n-3)] 0.023 ± 0.01a 0.028 ± 0.01a 0.13 ± 0.01c 0.079 ± 0.01b 0.018 ± 0.01a 0.066 ± 0.0b 0.24 ± 0.01e 0.20 ± 0.01d P < 0.0001‡ P < 0.0001iii ΔP < 0.0001
DPA[22:5(n-3)] 0.13 ± 0.018a 0.28 ± 0.018b 0.46 ± 0.017c 0.66 ± 0.018e 0.13 ± 0.018a 0.33 ± 0.014b 0.56 ± 0.018d 0.81 ± 0.018f P = 0.0009‡ P < 0.0001iv ΔP < 0.0001
DHA[22:6(n-3)] 12.80 ± 0.22 13.53 ± 0.21 14.38 ± 0.21 13.53 ± 0.22 13.52 ± 0.22 13.61 ± 0.17 15.06 ± 0.22 13.90 ± 0.22 P = 0.077‡ P < 0.0001v P = 0.26
∑SFA 36.00 ± 0.27 35.78 ± 0.26 35.74 ± 0.25 35.73 ± 0.26 36.35 ± 0.27 36.06 ± 0.21 35.77 ± 0.26 36.83 ± 0.27 P = 0.16 P = 0.074vi P = 0.091
∑MUFA 19.90 ± 0.16 20.44 ± 0.15 20.84 ± 0.15 20.1 ± 0.15 19.61 ± 0.16 20.08 ± 0.12 20.03 ± 0.15 19.82 ± 0.16 P = 0.021† P < 0.0001vii P = 0.14
∑n3PUFA 14.62 ± 0.21 15.53 ± 0.20 16.61 ± 0.19 15.85 ± 0.20 15.08 ± 0.21 15.46 ± 0.16 17.23 ± 0.20 16.29 ± 0.21 P = 0.14 P < 0.0001iii P = 0.21
∑n6PUFA 11.02 ± 0.20bd 10.70 ± 0.20b 9.80 ± 0.19b 10.65 ± 0.20bc 11.20 ± 0.21d 10.28 ± 0.16c 8.88 ± 0.20a 10.49 ± 0.20b P = 0.17 P < 0.0001ii ΔP = 0.023
ΔDifferent letters represent significance among means as determined by Bonferroni correction (P < 0.05).
Genotype Effect: †Lean > Obese; ‡Obese > Lean.
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In this study, we examined how incorporation of n3PUFA-
enriched soybean oil (SDA) into a westernized diet
influenced fatty acid composition and obesity-related
comorbidities. Our data show that SDA enhanced n3PUFA
profiles in lean and obese rodents. Furthermore, the mag-
nitude of this effect was consistent with established dietary
sources of n3PUFA, including marine and plant based oils.
The severity of obesity-associated dysfunction was also im-
proved with inclusion of SDA, which was evident from a
reduction in serum lipids and ectopic fatty liver. Collect-
ively, these findings show that SDA oil is a viable source of
n3PUFAs with potential therapeutic properties consistent
with FISH and FLAX [1-3].
As expected, the hyperphagic obese rodents had sig-
nificantly greater adiposity, dyslipidemia, and glucose in-
tolerance compared to lean counterparts. The omega-3
index was also modestly elevated in OZR rats, which
further corresponded to greater induction of PUFA-
associated genes. Interestingly, obese rodents exhibited
lower hepatic n6PUFA, with a particularly large reduc-
tion in AA. This finding was not consistent in extra-
hepatic tissues in which n6PUFA concentrations were
similar in OZR and LZR rats. Cao et al. [32] similarly
showed that fatty acid profiles between lean and obese
rodents were most different in the liver, but not in other
tissues when animals were provided equal amounts of
dietary n3PUFAs (i.e., the hyperphagic OZR rats were
pair-fed to lean counterparts). In the current study, diets
were fed ad libitum, which may account for the observa-
tion that AA was relatively lower in obese rats in the
current study compared to LA in the study by Cao et al.
[32]. As such, the relatively higher intake of n3PUFAs in
OZR rats may have specifically competed for the hepatic
desaturases and elongases resulting in lower AA.
The incorporation of dietary n3PUFA had no effect on
glucose homeostasis in the polygenic OZR rat. However,
previous studies have shown improved insulin sensitivity
with increased dietary n3PUFA intake in obese and dia-
betic mice [6,33]. Such a disparity in results likely reflects
differences in the animal models per se, use of purified
long chain PUFAs versus fish oil, disparities in absolute
daily intake of individual fatty acids, and variations in bio-
markers used to assess glucose metabolism (i.e., fasting
blood glucose vs. oral glucose tolerance). Nonetheless, ex-
perimental diets high in long-chain n3PUFA (i.e., FISH or
SDA) was associated with reduced fatty liver in obese rats,
a finding consistent with studies cited by Fedor et al. [33].
Consequently, these data indicate that hepatic insulin sen-
sitivity may be better maintained with increased consump-
tion of long-chain n3PUFAs.
All experimental diets resulted in greater total
n3PUFA and lower n6PUFA enrichment of erythrocytes
and liver compared to control (CON). However, theincorporation of a marine-based source of n3PUFA
(FISH) had the greatest impact on EPA and DHA en-
richment. This effect was consistent in erythrocytes and
in the majority of analyzed tissues (excluding skeletal
muscle where SDA tended to increase EPA and DHA to
a higher degree in obese rats). Previous studies [34,35]
have consistently shown fish oil consumption to be the
most efficient dietary intervention for increasing overall
tissue long chain n3PUFA content. This is undoubtedly
due to the large concentration of endogenous EPA and
DHA in fish oil, which enriches tissue without the need
for additional enzymatic modification in vivo as is the
case for ALA and to a lesser extent SDA. The diffe-
rential mRNA abundance of hepatic desaturase and
elongase genes observed in both lean and obese rodents
provided FISH or SDA compared to FLAX is consistent
with the observation that dietary long-chain PUFAs do
down-regulate Fads1 and Fads2 in vivo and in vitro [36].
As expected, we also showed the lowest n6PUFA and
AA concentrations in erythrocytes, liver, and brain after
FISH consumption compared to the other diets. Con-
sumption of SDA resulted in the next lowest n6PUFA
and AA concentrations in erythrocytes, while reductions
of n6PUFA and AA compared to CON in brain and liver
by FLAX and SDA were similar. The reductions in
n6PUFAs and AA are likely due to the high endogenous
n3PUFA content in fish, SDA-enriched soybean and
flaxseed oils, as n3PUFAs have been shown to directly
impact the metabolism of n6PUFAs [37].
Despite a lower magnitude of n3PUFA tissue enrich-
ment, the metabolic profile with SDA was comparable to
the marine-based oil diet. In particular, we observed simi-
lar protection against dyslipidemia and hepatic steatosis
with SDA and FISH. These hypolipidemic effects may be
attributed to an equivalent rise in hepatic EPA content.
Willumsen et al. [38] previously showed that greater hep-
atic EPA, but not DHA, improved lipid homeostasis
through inhibition of VLDL production in rats. Addition-
ally, the high rate of peroxisomal retroconversion of DHA
[39] and docosapentaenoic acid (DPA; 22:5 n3) [40] to
EPA in rat liver further suggests that EPA may play a more
important role in lipid lowering. In our study, the rela-
tively low hepatic DHA content along with marginal SDA
levels indicates that the beneficial hypolipidemic proper-
ties of SDA are likely related to the increase in EPA bio-
synthesis following SDA consumption.
Plant-based sources of n3PUFA, such as flaxseed oil, are
primarily high in ALA, which exhibits a relatively low
in vivo conversion to EPA [18]. On the other hand,
n3PUFA-enriched soybean oil is high in ALA and SDA.
The latter is efficiently converted to EPA as the reaction is
not dependent on delta-6-desaturase (Fads2) activity—the
rate limiting enzyme in ALA’s conversion to EPA [22-25].
Accordingly, our data show that the EPA content in
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was greater with SDA vs. FLAX. This further corresponded
with greater total n3PUFA and omega-3 index with SDA
compared to FLAX groups. Although it is possible that the
lower percentage of flaxseed oil (relative to SDA oil) is re-
sponsible for these differences, it has been reported that an
increase in dietary ALA from 0.4% to 1.1% (of total kcal)
reduced ALA conversion from 9% to 3% [41]. In our study,
ALA represented 4.2% and 3.0% (of total kcal) for FLAX
and SDA diets. Thus, incorporation of more flaxseed oil
would likely result in less EPA, whereas SDA conversion to
EPA would be unaffected by increased ALA.
The lower EPA content in FLAX fed rodents may also
be due to greater competition between other fatty acids
in the flaxseed oil. For instance, linoleic acid (LA; 18:2
n-6) and oleic acid (OA; 18:1 n-9), are potential sub-
strates for Fads2 that can also compete with ALA for
binding [42]. The increased concentration of these alter-
nate substrates in flaxseed oil can subsequently reduce
ALA conversion even further [42,43]. In our study, OA
and LA represented 28% and 20% of the total fatty acid
content in the FLAX diet, which was also approximately
19% and 40% greater than the OA and LA content of
the SDA diet, respectively.
Several studies have suggested that the conversion effi-
ciency of ALA is also influenced by total n3PUFA con-
tent. Gibson et al. [44] showed that EPA biosynthesis
from ALA was reduced when the total n3PUFA in diet
was > 3% of total energy. The amount of n3PUFA in
FLAX was > 3% of total energy which would therefore
be expected to decrease ALA conversion (FLAX had ap-
proximately 12% of total energy from n3PUFAs). We
also observed the greatest induction of hepatic transcript
abundance for desaturases and elongases with FLAX.
Our findings are consistent with data that showed
desaturase enzyme activities in rat liver were distinctly
increased by flaxseed oil compared to fish oil [45].
In contrast, Igarashi and colleagues [46] reported that
deprivation of n3PUFA resulted in a significant enhance-
ment of ALA conversion through upregulation of Fads1,
Fads2, Elovl2, and Elovl5 mRNA in liver; however, they
also studied n3PUFA “deficient” diets which may ac-
count for the apparent discrepancy to our current obser-
vations which were not n3PUFA deficient. More recent
work [47] has suggested that ALA conversion is more
effectively regulated by fatty acid substrate concentra-
tions than changes in the expression of desaturase or
elongase genes, which may explain how FLAX, which
had the greatest enzyme abundance also exhibited the
lower EPA biosynthesis compared to SDA.
Conclusion
The results of the present investigation are consistent with
previous data showing that SDA-enriched soybean oilmarkedly enhanced n3PUFA enrichment as evident from
erythrocyte and tissue profiles. Furthermore, we demon-
strated that SDA and FISH diets protected against several
obesity-related pathologies, including dyslipidemia and hep-
atic steatosis. Although not fully elucidated, we hypothesize
that these hypolipidemic properties were partially attributed
to hepatic EPA enrichment. Collectively, these data indicate
that SDA-enriched soybean oil is a viable plant-based alter-
native to traditional marine-based n3PUFA. In addition, in-
corporation of SDA-enriched soybean oil into the food
supply, as a more sustainable food ingredient, may increase
overall dietary n3PUFA intake which may help reduce the
prevalence of obesity-related disease.
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